News

                        Array
(
    [0] => stdClass Object
        (
            [id] => 1403
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => f28d3c7874e6fbb8a2f7.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2026-01-13
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2026-01-13 16:14:28
            [updated_time] => 2026-01-19 08:30:31
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Warning-of-fraudulent-impersonation-of-Eurofins-GENTIS-requesting-customers-to-transfer-money-for-early-delivery-of-test-results
            [title] => Warning of fraudulent impersonation of Eurofins GENTIS requesting customers to transfer money for early delivery of test results
            [description] => Dear Valued customers and partners,

            [content] => 
Recently, Eurofins GENTIS has received reports from several customers about unknown individuals calling by phone, impersonating company staff, and requesting payment of shipping fees for the delivery of test results (for NIPT tests and newborn screening tests), claiming that the results would be sent directly to the customers’ homes.

In response to this situation, Eurofins GENTIS would like to clearly affirm that the Company does not make phone calls requesting customers to transfer money via telephone or to personal accounts to pay any fees related to the delivery of test results. All service fees (if any) are publicly and transparently communicated at the time of registration and are implemented strictly in accordance with Eurofins GENTIS procedures. At the same time, we do not sell, provide, disclose, or allow the leakage of customers’ personal information in any form.
Currently, Eurofins GENTIS uses only one official customer service hotline: 1800 2010 to contact customers and notify them of test results. Any calls from other phone numbers requesting money transfers or personal information are not from Eurofins GENTIS.
In the context of rapid digital technology development, personal information may be collected from various sources and exploited for fraudulent activities, causing inconvenience and even serious impacts on customers’ rights and property. Therefore, Eurofins GENTIS kindly asks our partners and customers to remain vigilant, not to provide personal information, OTP codes, or bank account details, and not to transfer money without proper verification of the information.
Upon receiving any suspicious calls or unusual information related to test results, partners and customers are kindly requested to contact Eurofins GENTIS directly via the hotline 1800 2010 for timely verification and support.
Eurofins GENTIS sincerely thanks our valued partners and customers for their trust and companionship over the years, and kindly asks everyone to share this information with relatives and the community to help prevent unfortunate risks that may occur.
For further information, please contact:
EUROFINS GENTIS HANOI:
3rd Floor, V+ Shopping Center, 505 Minh Khai, Vinh Tuy Ward, Hanoi
EUROFINS GENTIS HO CHI MINH CITY:
8/24 Nguyen Dinh Khoi, Tan Son Nhat Ward, Ho Chi Minh City
Hotline: 1800 2010
Email: dichvu@gentis.com.vn
Sincerely,
            [content_more] => 
            [meta_title] => Warning of fraudulent impersonation of Eurofins GENTIS requesting customers to transfer money for ea
            [meta_description] => Dear Valued customers and partners,

            [meta_keyword] => GENTIS
            [thumbnail_alt] => 
            [post_id] => 1403
            [category_id] => 4
        )

    [1] => stdClass Object
        (
            [id] => 1400
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => 12313.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 1
            [displayed_time] => 2026-01-08
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2026-01-08 15:21:13
            [updated_time] => 2026-01-15 10:03:53
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Eurofins-GENTIS-honored-to-participate-in-the-reproductive-genetics-PGT-conference-2026
            [title] => Eurofins GENTIS honored to participate in the reproductive genetics & PGT conference 2026
            [description] => On January 18, 2026, at New World Saigon Hotel, Ho Chi Minh City, the Ho Chi Minh City Society of Reproductive Endocrinology & Infertility (HOSREM) – one of the most reputable professional organizations in reproductive medicine in Vietnam – in collaboration with specialized partners, will organize the Reproductive Genetics & PGT Conference.
            [content] => 

For many years, HOSREM has played a pioneering role in connecting the professional community, updating advances in reproductive medicine, and improving the quality of infertility treatment in Vietnam.
This year’s conference continues to serve as a key scientific forum, bringing together leading experts, physicians, and researchers to exchange knowledge, share experiences, and introduce the latest achievements in reproductive genetics, PGT technology, and modern assisted reproduction.
Eurofins introduces its speaker at the conference
At this year’s Reproductive Genetics & PGT Conference, Eurofins GENTIS is honored to present an in-depth scientific presentation, demonstrating its strong commitment to the development of assisted reproductive medicine:
Pham Dinh Minh, PhD (R&D Director, Eurofins GENTIS): “Trends and Applications of AI and Omics Data in Genetic Testing and Counseling for Assisted Reproduction”
With extensive expertise in bioinformatics, genetic technology, and artificial intelligence, Dr. Pham Dinh Minh will present:

Development trends of AI & Omics data in modern reproductive medicine

Applications of AI & Omics in genetic testing and counseling for assisted reproduction

Personalized treatment solutions to enhance clinical effectiveness



Eurofins GENTIS – Main sponsor of the reproductive genetics & PGT conference 2026
Eurofins GENTIS is proud to accompany the Conference as the Main Sponsor, demonstrating its long-term commitment to promoting genetic research and application, and improving the quality of assisted reproductive services in Vietnam.
At the event, the Eurofins GENTIS booth promises to offer many engaging activities for distinguished delegates. It will be a hub for updating the latest testing methods and technologies in assisted reproduction, helping to enhance clinical outcomes for patients.
Visitors will also have the opportunity to engage directly with Eurofins GENTIS’ experienced experts, receive answers regarding testing procedures, and explore the latest technological innovations that Eurofins GENTIS is actively researching and developing.
In addition, the Eurofins GENTIS booth will host exciting minigame activities with many lovely appreciation gifts for conference participants.
Eurofins GENTIS respectfully invites all physicians, specialists, and guests to visit its booth at the Reproductive Genetics & PGT Conference 2026 on:
 

Sunday, January 18, 2026
New World Saigon Hotel, Ho Chi Minh City 

Let us join hands with HOSREM and Eurofins GENTIS in advancing reproductive healthcare quality and creating new opportunities for future families.
We look forward to welcoming you at the Eurofins GENTIS booth.


            [content_more] => 
            [meta_title] => Eurofins GENTIS honored to participate in the reproductive genetics & PGT conference 2026
            [meta_description] => On January 18, 2026, at New World Saigon Hotel, Ho Chi Minh City, the Ho Chi Minh City Society of Reproductive Endocrinology & Infertility (HOSREM) – one of the most reputable professional organizations in reproductive medicine in Vietnam – in collaborati
            [meta_keyword] => GENTIS
            [thumbnail_alt] => 
            [post_id] => 1400
            [category_id] => 4
        )

    [2] => stdClass Object
        (
            [id] => 1399
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => 28_thể_ẩn.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 1
            [displayed_time] => 2025-12-31
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-12-31 14:41:49
            [updated_time] => 2026-01-15 09:59:00
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Eurofins-GENTIS-launches-GEN28-carrier-screening-test-for-28-recessive-genetic-disorders
            [title] => Eurofins GENTIS launches GEN28 – carrier screening test for 28 recessive genetic disorders
            [description] => On the journey of parenthood, nothing is more important than ensuring a child is born healthy. In reality, many individuals who appear completely healthy may unknowingly carry recessive genetic mutations. When both partners carry the same recessive gene, the risk of having a child affected by serious genetic disorders can be as high as 25%, leading to long-term impacts on health and quality of life.
            [content] => 
Therefore, as a leading institution in the number of recessive carrier screenings, Eurofins GENTIS has researched and developed GEN28 – Screening of 28 Genetic Disease Genes, designed to identify carriers, assess hereditary risks for offspring, and provide personalized genetic counseling—helping families embark on parenthood with maximum peace of mind.

GEN28 Test – screening of 28 recessive genetic disease genes
GEN28 is a screening test for 28 common and severe recessive genetic disease genes, performed using Next Generation Sequencing (NGS) technology. The test detects individuals who carry recessive disease genes. These conditions are often difficult to treat, require long-term care, and have lifelong effects on patients’ health and quality of life. With GEN28, couples can identify genetic risks early and proactively choose safe and healthy reproductive options.

Detection Scope: 28 recessive genetic disease genes
Method: GEN28 is conducted using Next Generation Sequencing (NGS). Sequencing data are processed and analyzed using specialized bioinformatics software.
Sample Type:
- 2–3 ml of whole blood collected in EDTA tubes.
- For patients undergoing GEN28 together with NIPT testing: a single 7–10 ml sample collected in the NIPT tubes currently used at Eurofins GENTIS is sufficient; no additional EDTA tube is required.
Turnaround Time: 8–10 working days

Diseases screened by GEN28
The 28 genes are associated with 25 inherited syndromes and disorders, including:

Alpha thalassemia
Beta thalassemia
Pendred syndrome / DFNB4 non-syndromic hearing loss
G6PD deficiency
Citrin deficiency
Pompe disease
Wilson disease
Phenylketonuria
Classic galactosemia (Type I)
Galactosemia Type II deficiency
Ornithine Transcarbamylase deficiency
Smith-Lemli-Opitz syndrome
Tay-Sachs disease
Fabry disease
5-alpha-reductase deficiency
Cystic fibrosis
X-linked adrenoleukodystrophy
Metachromatic leukodystrophy
Glutaric acidemia type II
Spinal muscular atrophy with respiratory distress type 1
Niemann-Pick disease
Primary carnitine deficiency
Autosomal recessive polycystic kidney disease
Hemophilia A
Hemophilia B



Benefits of GEN28 carrier screening
The GEN28 test offers significant benefits for families. If no disease-carrying gene is detected, couples can confidently plan for pregnancy with minimal concern about genetic risks. If only one partner is a carrier, detailed genetic counseling will be provided, along with an appropriate monitoring plan to ensure a safe pregnancy. When both partners carry the same disease gene, GEN28 enables couples to proactively choose safe reproductive options and effectively prevent disease transmission to their children. For families with a history of genetic disorders, the test helps identify disease-causing genes and provides genetic counseling to minimize hereditary risks for future generations.
With GEN28 by Eurofins GENTIS, healthcare planning becomes more proactive and reassuring. The test enables early detection of recessive genetic carriers, assesses the risk of disease transmission to offspring, and supports couples in making safe and informed reproductive decisions. In addition, GEN28 is accompanied by personalized genetic counseling services, delivering accurate information and practical guidance—helping families fully understand their genetic health and prepare for a healthier future for their children.


            [content_more] => 
            [meta_title] => Eurofins GENTIS launches GEN28 – carrier screening test for 28 recessive genetic disorders
            [meta_description] => On the journey of parenthood, nothing is more important than ensuring a child is born healthy. In reality, many individuals who appear completely healthy may unknowingly carry recessive genetic mutations. When both partners carry the same recessive gene, 
            [meta_keyword] => GENTIS,GEN28
            [thumbnail_alt] => 
            [post_id] => 1399
            [category_id] => 4
        )

    [3] => stdClass Object
        (
            [id] => 1398
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => 605764480_1275897227908799_5804145375518154194_n.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-12-29
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-12-29 08:29:14
            [updated_time] => 2026-01-15 09:52:40
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Congratulations-on-the-successful-December-prenatal-class-The-journey-to-happy-motherhood-of-Andrology-and-Fertility-hospital-of-Hanoi
            [title] => Congratulations on the successful December prenatal class – The journey to happy motherhood of Andrology and Fertility hospital of Hanoi
            [description] => On the morning of December 27, 2025, at the 5th Floor Hall – Building A, Andrology and Fertility hospital of Hanoi, the program “Prenatal Class – The Journey to Happy Motherhood” was successfully held, leaving many deep emotions and meaningful values for all expectant mothers and their families in attendance. The program was not only a simple medical knowledge-sharing session but also a journey of spreading love, understanding, and strong faith for families preparing to welcome their little angels.
            [content] => 
Prenatal class – A strong foundation for the journey of motherhood
Pregnancy and childbirth are sacred journeys, yet they are also accompanied by many worries and concerns, especially for first-time mothers or families who have experienced the long and challenging journey of infertility. Understanding this, Hanoi Andrology and Fertility Hospital, in collaboration with the Happy Home Association, organized the Prenatal Class – The Journey to Happy Motherhood with the hope of providing expectant mothers with scientific knowledge, emotional stability, and the most comprehensive preparation before their delivery day.

From early morning, the hall welcomed a large number of expectant mothers and their families, creating a warm, intimate atmosphere filled with positive energy. The enthusiastic participation of families clearly reflected the strong demand for systematic prenatal education and the trust they place in the hospital’s medical team.
Experienced doctors accompanying Parents-to-be
The program was honored to have the direct participation and sharing of experienced obstetrics and gynecology specialists from Hanoi Andrology and Fertility Hospital:
 Dr. Nguyen Thi Hong Nhung, Specialist in Obstetrics and Gynecology, and Dr. Dam Dinh Tam, Specialist in Obstetrics and Gynecology.

With solid professional expertise and years of experience accompanying thousands of childbirth cases, the doctors delivered practical, easy-to-understand, and highly relevant information. The class focused on key concerns such as physical changes during pregnancy, signs of labor, natural birth and cesarean section procedures, pain management during labor, postpartum care for both mother and baby, as well as psychological preparation for welcoming the newborn.
Beyond one-way knowledge sharing, the doctors devoted significant time to directly answering every question from expectant mothers and their families — from simple concerns about nutrition and safe exercise to deeper worries about the childbirth process — all were carefully listened to and thoroughly advised.
Providing official medical knowledge – Confidence for a safe delivery
One of the most outstanding values of the prenatal class was the provision of official medical knowledge based on professional guidelines and clinical practice. This helped expectant mothers avoid misleading and unverified information widely circulating on social media.

Through the class, mothers gained a better understanding of their own bodies, learned how to listen to changes during pregnancy, and recognized early signs that require medical attention. More importantly, with sufficient knowledge and strong psychological preparation, mothers felt much more confident and reassured when approaching childbirth — a sacred and unforgettable milestone in life.
Many participants shared that after the session, they felt more relaxed, less anxious, and more confident about the journey ahead. This is precisely the goal Hanoi Andrology and Fertility Hospital always strives for when organizing its regular prenatal classes.
A loving connection space for the whole family
Not only for expectant mothers, the prenatal class also created an opportunity for future fathers and family members to join, listen, and better understand the journey of pregnancy and childbirth. Family support is a powerful source of emotional strength, helping mothers feel more secure and happy.

The class atmosphere was open and friendly, where everyone could share their own stories, emotions, and experiences. This meaningful connection helped form a warm community where families prepared for parenthood with a proactive and positive mindset.
Eurofins GENTIS – Proud to be the accompanying sponsor
Contributing significantly to the success of the program, Eurofins GENTIS was honored to be the accompanying sponsor of the Prenatal Class – The Journey to Happy Motherhood. With the mission of providing high-quality testing solutions and healthcare services, Eurofins GENTIS continuously supports Vietnamese families in achieving safe and healthy pregnancies and childbirth.
Their companionship not only ensured a well-organized and meaningful program but also reflected a long-term commitment to maternal and child healthcare, especially during the prenatal stage — the foundation for a child’s comprehensive development in the future.
In the coming time, Eurofins GENTIS will continue accompanying the regular prenatal classes of Hanoi Andrology and Fertility Hospital, contributing to the best possible physical and emotional preparation for expectant mothers before childbirth. Because Eurofins GENTIS understands that each class is not just a knowledge-sharing session, but also a meaningful milestone that builds mothers’ confidence, strengthens family bonds, and makes the journey of parenthood gentler and happier.
The Prenatal Class – The Journey to Happy Motherhood on December 27, 2025 concluded in a warm atmosphere filled with joy and trust. The success of the program once again affirms the continuous efforts of Hanoi Andrology and Fertility Hospital in providing comprehensive care for families, along with the valuable support of partners such as Eurofins GENTIS.
We wish all expectant mothers good health, peace of mind, a fulfilling pregnancy, and a smooth, gentle delivery. May all families soon welcome their beloved babies, opening a new chapter filled with happiness and love.

            [content_more] => 
            [meta_title] => Congratulations on the successful December prenatal class – The journey to happy motherhood of Andro
            [meta_description] => On the morning of December 27, 2025, at the 5th Floor Hall – Building A, Andrology and Fertility hospital of Hanoi, the program “Prenatal Class – The Journey to Happy Motherhood” was successfully held, leaving many deep emotions and meaningful values for 
            [meta_keyword] => GENTIS
            [thumbnail_alt] => 
            [post_id] => 1398
            [category_id] => 4
        )

    [4] => stdClass Object
        (
            [id] => 1397
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => 299d08137c20f37eaa31.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-12-26
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-12-26 15:55:42
            [updated_time] => 2026-01-14 15:50:20
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Eurofins-GENTIS-&-andrology-and-fertility-hospital-of-Hanoi-announce-research-on-recurrent-pregnancy-loss-The-role-of-multigene-sequencing-in-genetic-screening-and-counseling
            [title] => Eurofins GENTIS & andrology and fertility hospital of Hanoi announce research on recurrent pregnancy loss: The role of multigene sequencing in genetic screening and counseling
            [description] => Recently, the scientific study entitled “Recurrent Pregnancy Loss: The Role of Multigene Sequencing in Genetic Screening and Counseling,” conducted by Eurofins GENTIS and the Hanoi Hospital of Andrology and Infertility, was officially published in Issue No. 197 of the Journal of Medical Research.
            [content] => 

The study was conducted with the objective of investigating the spectrum of genetic variants detected by FertiScan™ (a test designed to identify genetic abnormalities associated with female infertility and recurrent pregnancy loss) in women with a history of recurrent miscarriage.
The study population consisted of 20 infertile women with a history of recurrent pregnancy loss (RPL). RPL was defined as two or more consecutive spontaneous miscarriages before 20 weeks of gestation at the Hanoi Hospital of Andrology and Infertility from May to August 2023.
The study indicates that recurrent miscarriage and repeated fetal loss are common challenges in assisted reproductive practice, affecting approximately 1–5% of women of reproductive age. In addition to uterine anatomical, endocrine, immunohematological, and infectious causes, genetic factors play an important role but are not easily detected by routine testing. The cause of miscarriage remains unknown in more than 50% of these cases.
Karyotype analysis and microarray testing are useful for identifying chromosomal numerical and structural abnormalities, but they remain limited in detecting single-gene causes related to oocyte development, meiosis, implantation, and early embryonic viability. Therefore, targeted molecular genetic approaches are receiving increasing attention.
In recent years, next-generation sequencing (NGS) panels have enabled simultaneous analysis of multiple genes related to female reproduction, expanding the ability to identify genetic etiologies in patients with recurrent miscarriage and fetal loss. Among these, the FertiScan™ Global Female Infertility Panel is a representative tool, covering more than 70 genes involved in key pathogenic mechanisms including premature ovarian failure and ovarian dysfunction, ovarian dysgenesis, defects in oocyte maturation, abnormal oocyte–zona pellucida–fertilization interactions, genes affecting implantation and endometrial signaling, as well as DNA repair genes associated with early embryonic lethality.
This approach not only increases the detection rate of clinically significant genetic variants but also supports personalized counseling and intervention strategies, including partner testing in autosomal recessive disorders, indications for PGT-M or PGT-SR, and prenatal genetic screening when appropriate.
In Vietnam, data on the prevalence of genetic variants in women with unexplained recurrent pregnancy loss remain limited. This gap restricts optimal prognostic counseling and personalized treatment, particularly in cases with normal karyotype results but persistent pregnancy loss.
The implementation of specialized targeted NGS panels such as FertiScan™ provides value in identifying subsets of patients carrying pathogenic or likely pathogenic variants truly associated with reproductive biological mechanisms, and in documenting variants of uncertain significance (VUS) within the Vietnamese population in order to gradually standardize variant interpretation according to the classification guidelines of the American College of Medical Genetics and Genomics (ACMG). FertiScan™ results are interpreted following ACMG/AMP (American College of Medical Genetics and Genomics/Association for Molecular Pathology) variant classification guidelines, including pathogenic (P), likely pathogenic (LP), variant of uncertain significance (VUS), and benign/likely benign. Variant classification is always considered within the specific clinical and family context to ensure individual appropriateness.
From an application perspective, FertiScan™ enhances the detection of monogenic causes in patients with recurrent pregnancy loss, particularly in cases without chromosomal abnormalities identified by karyotype or microarray. The test also supports personalized genetic counseling, including partner testing in recessive genetic conditions, recommendations for PGT-M/PGT-SR, and the development of appropriate prenatal or preconception screening plans. Furthermore, FertiScan™ demonstrates strong potential for application in genetic epidemiology research in Vietnam, contributing to the establishment of population-based variant databases, thereby improving the accuracy of variant interpretation and the quality of diagnosis, counseling, and future interventions.
These results highlight the importance of systematically integrating genetic testing into the evaluation of recurrent miscarriage and fetal loss, with multigene testing positioned within structured pre- and post-test counseling and long-term follow-up strategies.
With the mission of “Enhancing the intellectual and physical well-being of the Vietnamese people,” Eurofins GENTIS continues its collaboration with the Hanoi Hospital of Andrology and Infertility to implement high-value medical research and to further develop a comprehensive ecosystem of advanced genetic testing. Through these efforts, Eurofins GENTIS contributes to delivering modern healthcare solutions and supporting medical professionals in improving reproductive healthcare for the community.
            [content_more] => 
            [meta_title] => Eurofins GENTIS & andrology and fertility hospital of Hanoi announce research on recurrent pregnancy
            [meta_description] => Recently, the scientific study entitled “Recurrent Pregnancy Loss: The Role of Multigene Sequencing in Genetic Screening and Counseling,” conducted by Eurofins GENTIS and the Hanoi Hospital of Andrology and Infertility, was officially published in Issue N
            [meta_keyword] => GENTIS
            [thumbnail_alt] => 
            [post_id] => 1397
            [category_id] => 4
        )

    [5] => stdClass Object
        (
            [id] => 1396
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => 06f14a7e3e4db113e85c.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-12-26
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-12-26 08:41:18
            [updated_time] => 2026-01-14 15:41:21
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Eurofins-GENTIS-&-Andrology-and-fertility-hospital-of-Hanoi-publish-research-findings-on-recurrent-pregnancy-loss-in-the-journal-of-medical-research
            [title] => Eurofins GENTIS & Andrology and fertility hospital of Hanoi publish research findings on recurrent pregnancy loss in the journal of medical research
            [description] => Recently, Eurofins GENTIS and the Hanoi Hospital of Andrology and Infertility officially published the results of their scientific study evaluating the role of multigene sequencing (NGS) — specifically the FertiScan™ panel — in identifying genetic causes in women with a history of recurrent pregnancy loss (RPL).
            [content] => 
The research findings were presented in the scientific article entitled: “Recurrent Pregnancy Loss: The Role of Multigene Sequencing in Genetic Screening and Counseling,” which was published in Journal of Medical Research, Issue No. 197, December 2025 — a prestigious journal featuring original research and review articles in basic medicine, clinical medicine, preventive medicine, public health, and medical sociology, aimed at advancing medical knowledge and practice.

The study was conducted on 20 infertile patients with a history of recurrent pregnancy loss at the Hanoi Hospital of Andrology and Infertility between May and August 2023. According to experts, recurrent miscarriage and fetal loss represent a major challenge in assisted reproduction, affecting approximately 1–5% of women of reproductive age.

In recent years, next-generation sequencing (NGS) panels have enabled simultaneous analysis of multiple genes related to female reproduction, significantly expanding the ability to identify genetic etiologies in patients with recurrent miscarriage and fetal loss.
Among these tools, the FertiScan™ Global Female Infertility Panel is particularly comprehensive, covering more than 70 genes involved in key pathogenic mechanisms, including: Premature ovarian failure and ovarian dysfunction. Ovarian dysgenesis. Oocyte maturation defects. Abnormal oocyte–zona pellucida–fertilization interactions. Genes affecting implantation and endometrial signaling. DNA repair genes associated with early embryonic lethality
In this study, researchers used the FertiScan™ Global Female Infertility Panel (70 genes) based on NGS technology to simultaneously examine coding regions and splice sites of the target genes.
Among the 20 patients, 12 cases (60%) carried ≥ 1 reproduction-related genetic variant, including: 4 patients harboring pathogenic or likely pathogenic variants (P/LP). Predominantly in the heterozygous state of autosomal recessive disorders.
A substantial proportion of detected variants were classified as variants of uncertain significance (VUS). Notably, variants were identified in genes with well-established biological roles, such as CEP250, TACR3, NOBOX, ZP1, and others.
The FertiScan™ test which identifies genetic causes of infertility and rare hereditary abnormalities associated with female infertility and recurrent miscarriage, as well as evaluates male reproductive health — significantly enhances the detection of monogenic causes in patients with RPL, particularly in cases without chromosomal abnormalities detected by karyotyping or microarray analysis.
The test also supports personalized genetic counseling, including: Partner testing in autosomal recessive conditions. Indications for PGT-M (preimplantation genetic testing for monogenic diseases). PGT-SR (preimplantation genetic testing for structural chromosomal rearrangements). Development of tailored prenatal and preconception screening strategies
Beyond its clinical value, FertiScan™ demonstrates strong potential in genetic epidemiology research in Vietnam, contributing to the establishment of population-specific variant databases and thereby improving variant interpretation, diagnostic accuracy, counseling, and future clinical interventions.
Researchers concluded that multigene testing such as FertiScan™ significantly improves the detection of underlying causes in unexplained RPL cases, particularly when integrated into comprehensive pre- and post-test counseling and long-term follow-up.
Sharing insights on the study, Dr. Pham Dinh Minh, R&D Director of Eurofins GENTIS and co-author of the publication, stated:“Publishing in the Journal of Medical Research is a long journey — from idea generation, study implementation, data analysis, manuscript preparation, submission, to rigorous peer review. Beyond scientific merit, the research must demonstrate strict methodological rigor and data integrity. We spent more than three months collecting data and over two years completing the project. The publication of this work is a source of pride for our team and opens new avenues for research in infertile women with recurrent pregnancy loss, helping realize the dream of parenthood for many couples and highlighting the immense potential of genetic applications in reproductive medicine in Vietnam.”
Through systematically conducted research and publication in prestigious scientific journals, Eurofins GENTIS and the Hanoi Hospital of Andrology and Infertility continue to reaffirm their joint commitment to advancing genetic research and its integration into clinical practice — contributing to improved diagnostic and treatment quality in assisted reproduction across Vietnam.
            [content_more] => 
            [meta_title] => Eurofins GENTIS & Andrology and fertility hospital of Hanoi publish research findings on recurrent p
            [meta_description] => Recently, Eurofins GENTIS and the Hanoi Hospital of Andrology and Infertility officially published the results of their scientific study evaluating the role of multigene sequencing (NGS) — specifically the FertiScan™ panel — in identifying genetic causes 
            [meta_keyword] => GENTIS
            [thumbnail_alt] => 
            [post_id] => 1396
            [category_id] => 4
        )

    [6] => stdClass Object
        (
            [id] => 1395
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => 603924137_1486168513515857_3858940485546585452_n.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-12-25
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-12-25 13:18:45
            [updated_time] => 2026-01-14 15:26:26
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Eurofins-GENTIS-pioneers-the-deployment-of-Next-generation-sequencing-technology-MiSeq-i100-Plus-in-Vietnam
            [title] => Eurofins GENTIS pioneers the deployment of Next-Generation sequencing technology MiSeq i100 Plus in Vietnam
            [description] => Eurofins GENTIS has officially marked a major milestone by becoming the first organization in Vietnam to install and deploy the MiSeq i100 Plus system — the latest next-generation sequencing (NGS) technology from Illumina. This achievement strongly affirms Eurofins GENTIS’s long-term commitment to continuously advancing genetic diagnostic capabilities and aligning with the highest standards of modern global medicine.
            [content] => 
The MiSeq i100 Plus is Illumina’s newest benchtop sequencer — from the world’s leading brand in NGS technology. More than a conventional sequencing instrument, the MiSeq i100 Plus represents a significant leap forward in performance, speed, and accuracy, meeting the ever-growing demands of clinical and research laboratories.

Eurofins GENTIS’s pioneering adoption of this system clearly reflects its strategic, long-term investment vision to deliver the most advanced genetic testing solutions to the community.

One of the most outstanding advantages of the MiSeq i100 Plus is its exceptional sequencing speed. By leveraging advanced chemistry and an optimized workflow, the system significantly shortens run times, enabling many NGS-based tests to deliver same-day results while maintaining high accuracy and data reliability.

 This capability is particularly critical in clinical settings requiring rapid decision-making, allowing physicians to implement timely and effective treatment strategies.
In addition to speed, the MiSeq i100 Plus features a “Touch & Run” plug-and-play design, simplifying complex technical procedures. The integrated reagent cartridge minimizes manual preparation steps, thereby reducing human error and enhancing consistency between runs. With its user-friendly design and high level of automation, Eurofins GENTIS’s technical team can operate the system smoothly and reliably, while dedicating greater focus to in-depth analysis and rigorous quality control.
The system incorporates Illumina’s proprietary XLEAP-SBS™ technology, delivering superior read quality and significantly improving the accuracy and reliability of sequencing data. This allows the platform to precisely detect and analyze complex genetic variants, meeting the stringent requirements of modern genetic testing across both clinical and research applications.

With installation, technology transfer, and continuous technical support from Mitalab, Eurofins GENTIS is maximizing the capabilities of the MiSeq i100 Plus across multiple critical fields of medicine and molecular biology.
NGS enables accurate analysis of chromosomal abnormalities and pathogenic genetic variants, significantly enhancing reproductive health counseling and care, and helping many families realize their dream of parenthood.
The MiSeq i100 Plus plays a pivotal role in early detection of cancer-related genetic mutations, comprehensive tumor genomic profiling, and the development of targeted treatment regimens.
 This forms the foundation of precision medicine, where each patient receives therapies tailored to their unique genetic profile — improving treatment outcomes and quality of life.
The system expands capabilities in diagnosing rare diseases and conducting high-sensitivity microbial studies, enabling the detection of novel or hard-to-identify pathogens beyond the limits of conventional methods.
 These advancements contribute not only to clinical effectiveness but also to biomedical research and healthcare development in Vietnam.
Becoming the first organization in Vietnam to deploy the MiSeq i100 Plus once again reinforces Eurofins GENTIS’s leadership position in genetic testing and diagnostics.
 This milestone reflects not only technological achievement but also the company’s strategic vision, deep professional expertise, and long-term commitment to bringing the world’s most advanced medical technologies closer to the Vietnamese community.
Looking ahead, Eurofins GENTIS will continue making strong investments in technological infrastructure, human resources, and international collaboration — partnering with the healthcare sector to elevate diagnostic quality, advance personalized medicine, and safeguard public health.

            [content_more] => 
            [meta_title] => Eurofins GENTIS pioneers the deployment of Next-Generation sequencing technology MiSeq i100 Plus in 
            [meta_description] => Eurofins GENTIS has officially marked a major milestone by becoming the first organization in Vietnam to install and deploy the MiSeq i100 Plus system — the latest next-generation sequencing (NGS) technology from Illumina. This achievement strongly affirm
            [meta_keyword] => GENTIS
            [thumbnail_alt] => 
            [post_id] => 1395
            [category_id] => 4
        )

    [7] => stdClass Object
        (
            [id] => 1394
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => thong-bao-eurofins-gentis-lam-việc-xuyen-tết-dương-lịch-2026.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-12-25
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-12-25 08:41:05
            [updated_time] => 2026-01-14 15:16:21
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Eurofins-GENTIS-operates-throughout-New-Year’s-day-2026
            [title] => Eurofins GENTIS operates throughout New Year’s day 2026
            [description] => As the vibrant atmosphere of the new year approaches, Eurofins GENTIS would like to respectfully inform our valued Customers and Partners of our official working schedule for New Year’s Day – January 1, 2026. In order to best meet the growing demands for testing services, consultation, and technical support, Eurofins GENTIS will continue operating throughout the New Year holiday, ensuring that all services remain uninterrupted, timely, and efficient.
            [content] => 
Eurofins GENTIS understands that New Year is a period when demand for medical testing — especially genetic testing, DNA paternity testing, NIPT for pregnant women, and advanced analytical services — increases significantly.
 Therefore, maintaining continuous operations not only reflects our strong sense of responsibility, but also reaffirms our commitment to safeguarding community health and supporting our customers whenever they need us.
Eurofins GENTIS – Always ready to serve during New Year’s 2026
With the motto “Serving with Quality”, Eurofins GENTIS will operate normally on January 1, 2026, including:


Receiving test samples directly in Hanoi and Ho Chi Minh City


Providing remote consultation via hotline 1800 2010


Processing and delivering test results according to standard procedures


Answering all inquiries related to genetic and gene testing





Our continuous operation during the public holiday demonstrates the collective effort of the entire Eurofins GENTIS system to deliver seamless, uninterrupted service.
 Even on holidays, our team of experts, technicians, and customer care staff remain fully available to provide fast, accurate, and dedicated support.
Enhancing service quality – dedicated care even during the holiday
Beyond ensuring uninterrupted operations, Eurofins GENTIS remains firmly committed to strict quality standards across all services.
 As a member of the Eurofins Group — one of the world’s leading testing corporations — we apply internationally recognized quality management systems, ensuring high-accuracy results and optimized turnaround times.
Among the most in-demand services during the year-end period are:
NIPT – Non-Invasive prenatal testing
NIPT services at Eurofins GENTIS are conducted in CAP-accredited laboratories, the global gold standard for clinical laboratory quality.
 This allows expectant mothers to confidently assess fetal chromosomal abnormality risks and safeguard their pregnancy journey for the coming year.
DNA paternity testing
Demand for parent–child DNA testing increases toward year-end.
 Eurofins GENTIS provides highly accurate, strictly confidential services with flexible turnaround times suitable for both personal consultation and legal purposes.
Molecular genetic testing – Solutions for treatment & disease monitoring
Through genetic and gene testing, Eurofins GENTIS supports clients in building proactive, effective healthcare plans.
 Across all services — even during public holidays — we strictly follow international standards, meeting the highest expectations of our customers and partners.
Customer appreciation – A meaningful journey together
As 2025 draws to a close, Eurofins GENTIS reflects on a year of remarkable progress: launching advanced services, improving processes, upgrading operational systems, and expanding professional collaborations.
 Most importantly, we are deeply honored by the trust of hundreds of thousands of customers and partners nationwide.
On the occasion of New Year 2026, we extend our heartfelt thanks to:


Our valued customers for their continued trust


Our partners for their enduring cooperation


Our dedicated staff for their tireless efforts throughout the year




Your support empowers Eurofins GENTIS to continue pursuing our mission:
 Enhancing the intellectual and physical well-being of the Vietnamese people.
 We look forward to remaining your trusted companion in healthcare for individuals, families, and communities in 2026.
Holiday support contact information
For timely assistance during the New Year holiday, please contact:
 Toll-free Hotline: 1800 2010 (including January 1, 2026)
Or visit our offices:
Hanoi: 3rd Floor, V+ Commercial Center, 505 Minh Khai, Vinh Tuy Ward, Hanoi
 Ho Chi Minh City: 8/24 Nguyen Dinh Khoi, Tan Son Nhat Ward, Ho Chi Minh City
Our professional consultants and technicians are always ready to assist with sample reception, consultation, and result delivery, ensuring maximum convenience for customers during the holiday.
New year wishes – A peaceful and radiant beginning
New Year’s Day is not only a brief holiday but also a meaningful milestone marking a fresh start.
 On this occasion, Eurofins GENTIS sincerely wishes our Customers and Partners:


A prosperous and successful 2026


Peace of mind and strong health


Abundant positive energy to conquer new goals


We believe that through mutual trust and sustainable partnership, Eurofins GENTIS and our Customers/Partners will create a brilliant, successful, and inspiring 2026 together.
            [content_more] => 
            [meta_title] => Eurofins GENTIS operates throughout New Year’s day 2026
            [meta_description] => As the vibrant atmosphere of the new year approaches, Eurofins GENTIS would like to respectfully inform our valued Customers and Partners of our official working schedule for New Year’s Day – January 1, 2026. In order to best meet the growing demands for 
            [meta_keyword] => GENTIS
            [thumbnail_alt] => 
            [post_id] => 1394
            [category_id] => 4
        )

)